• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Biological variation in urinary excretion of pyridinium crosslinks: recommendations for the optimum specimen.

作者信息

Panteghini M, Pagani F

机构信息

1st Laboratory of Clinical Chemistry, Spedali Civili, Brescia, Italy.

出版信息

Ann Clin Biochem. 1996 Jan;33 ( Pt 1):36-42. doi: 10.1177/000456329603300105.

DOI:10.1177/000456329603300105
PMID:8929064
Abstract

We assessed the analytical and biological variation of pyridinium crosslinks in early morning, 2 h fasting, and 24 h urine specimens from 14 healthy adults over a 1 month period. The results were expressed both in terms of pyridinoline concentration and pyridinoline/creatinine ratio. The data obtained were used to select the optimum specimen for clinical purposes. We found that: (a) early morning specimens are preferred; (b) results should be expressed as pyridinoline/creatinine ratio; (c) reference intervals should be stratified according to gender; (d) the necessary analytical imprecision (CV < or = 9%), derived from biological variation, is not easily achieved by current methods; (e) the difference between serial results from an individual must be > 50% to be statistically significant; and (f) assessment of risk for osteoporotic fracture by means of the pyridinium crosslink assay would, in a significant number of patients, require analysis of multiple urine specimens.

摘要

相似文献

1
Biological variation in urinary excretion of pyridinium crosslinks: recommendations for the optimum specimen.
Ann Clin Biochem. 1996 Jan;33 ( Pt 1):36-42. doi: 10.1177/000456329603300105.
2
Inter and intra-individual variations in urinary excretion of pyridinium crosslinks of collagen in healthy young adults.
Eur J Clin Nutr. 1998 Jan;52(1):71-3. doi: 10.1038/sj.ejcn.1600502.
3
Urinary excretion of pyridinium crosslinks in healthy 4-10 year olds.4至10岁健康儿童尿中吡啶交联物的排泄情况。
Arch Dis Child. 1999 Apr;80(4):370-3. doi: 10.1136/adc.80.4.370.
4
Posture, age, menopause, and osteopenia do not influence the circadian variation in the urinary excretion of pyridinium crosslinks.
J Bone Miner Res. 1994 Dec;9(12):1883-8. doi: 10.1002/jbmr.5650091207.
5
Urinary hydroxypyridinium crosslinks of collagen in population-based screening for overt vertebral osteoporosis: results of a pilot study.基于人群的显性椎体骨质疏松筛查中尿胶原羟基吡啶交联物:一项试点研究的结果
J Bone Miner Res. 1994 Sep;9(9):1433-40. doi: 10.1002/jbmr.5650090916.
6
Longitudinal study of urinary hydroxy-pyridinium cross-links and growth in healthy infants: higher values with breastfeeding and after daytime sleep.健康婴儿尿中羟基吡啶交联物与生长的纵向研究:母乳喂养及白天睡眠后水平更高
Exp Clin Endocrinol Diabetes. 1998;106(1):51-6. doi: 10.1055/s-0029-1211950.
7
Circadian variation of urinary excretion of elastin and collagen crosslinks.
Proc Soc Exp Biol Med. 1998 Jul;218(3):229-33. doi: 10.3181/00379727-218-44291.
8
Monitoring of free and total urinary pyridinoline and deoxypyridinoline in healthy volunteers: sample relationships between 24-h and fasting early morning urine concentrations.
Bone Miner. 1993 Apr;21(1):9-19. doi: 10.1016/s0169-6009(08)80116-x.
9
Evaluation of urinary pyridinium crosslink excretion as a marker of bone resorption in the rat.评估大鼠尿吡啶交联排泄作为骨吸收标志物的情况。
J Bone Miner Res. 1994 Aug;9(8):1211-9. doi: 10.1002/jbmr.5650090811.
10
Reliability of spot samples for assessment of urinary excretion of pyridinoline in patients with rheumatoid arthritis.用于评估类风湿性关节炎患者吡啶啉尿排泄的即时样本的可靠性。
Clin Exp Rheumatol. 2001 Jan-Feb;19(1):78-80.

引用本文的文献

1
Parathyroid hormone and bone marker levels in patients with morbid obesity before and after biliopancreatic diversion.病态肥胖患者在胆胰转流术前及术后的甲状旁腺激素和骨标志物水平
Obes Surg. 2007 Mar;17(3):348-54. doi: 10.1007/s11695-007-9063-9.
2
Fast and slow bone losers. Relevance to the management of osteoporosis.快速和缓慢骨质流失者。与骨质疏松症管理的相关性。
Drugs Aging. 1998;12 Suppl 1:1-7. doi: 10.2165/00002512-199812001-00001.
3
A proposal for standardizing urine collections for bone resorption markers measurement.关于规范用于骨吸收标志物测量的尿液收集的提议。
J Clin Lab Anal. 1998;12(3):145-9. doi: 10.1002/(sici)1098-2825(1998)12:3<145::aid-jcla3>3.0.co;2-8.